News and Trends 4 May 2015
Karolinska Development took a Step Back in its Biotech portfolio
The finances of Karolinska Development remain in a dangerous downward spiral as the company dropped to €136.9M (SEK 1,277 million), an unsatisfactory record for the company, the lowest valuation since 2011. For this purpose, the company decided to totally abandon investing in Pergamum, Umecrine and NeoDynamics AB, three biotech companies. Karolinska’s reaction is well-defined: the […]